Shanghai Medicilon Inc.

Equities

688202

CNE100003NQ8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-07 EDT			5-day change	1st Jan Change
41.73 ^CNY	+11.46%		+18.01%	-38.97%

04-28	Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	CI

Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

April 25, 2023 at 10:45 am

Shanghai Medicilon Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 451.4 million compared to CNY 355.99 million a year ago. Revenue was CNY 451.4 million compared to CNY 355.99 million a year ago.

Net income was CNY 101.57 million compared to CNY 77.19 million a year ago. Basic earnings per share from continuing operations was CNY 0.8357 compared to CNY 0.6357 a year ago. Diluted earnings per share from continuing operations was CNY 0.8357 compared to CNY 0.6357 a year ago.

Latest news about Shanghai Medicilon Inc.

Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	04-01	CI
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
Medicilon Appoints Dr. Qingcong Lin as President of Medicilon Usa Corp	03-11	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit	01-09	CI
Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	01-02	CI
Shanghai Medicilon Inc.(SHSE:688202) dropped from Shanghai Stock Exchange Health Care Sector Index	12-08	CI
Shanghai Medicilon Inc. announces an Equity Buyback for CNY 40 million worth of its shares.	11-13	CI
Shanghai Medicilon Inc. authorizes a Buyback Plan.	11-12	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Fosun Health Capital Reaches Cooperation Agreement with Medicilon to Explore Innovative Drug Research and Development Together	23-07-31	CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Shanghai Medicilon Logs 28.6% Jump in 2022 Profit	23-02-21	MT
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-20	CI
Shanghai Medicilon Gets Securities Regulator's Nod to Issue Stocks	23-02-14	MT
Certain A Shares of Shanghai Medicilon Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2022.	22-11-05	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Shanghai Medicilon Inc. announced that it expects to receive CNY 2.16 billion in funding	22-02-09	CI
Shanghai Medicilon Inc.(SHSE:688202) added to Shanghai Stock Exchange Health Care Sector Index	21-12-13	CI
Shanghai Medicilon Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI

Chart Shanghai Medicilon Inc.

Duration

Period

More charts

Company Profile

Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.73

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI MEDICILON INC.	-38.97%	778M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	+7.02%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs